7:04AM Santarus announces presentation of Phase III data for Rifamycin SV MMX in Travelers' Diarrhea (SNTS) 22.58 : Co announced that new data from its Phase III clinical study with the investigational drug rifamycin SV MMX in patients with travelers' diarrhea will be featured in a poster presentation at IDWeek in San Francisco at the Moscone Center (Poster Hall C) from 12:30 p.m. to 2:00 p.m. Pacific Time on Saturday, Oct 5, 2013. IDWeek is the combined annual meeting of the Infectious Diseases Society of America (IDSA), the Society for Healthcare Epidemiology of America (SHEA), the HIV Medicine Association (HIVMA), and the Pediatric Infectious Diseases Society (PIDS).
"The data from this clinical study indicate that rifamycin SV MMX significantly shortened the duration of travelers' diarrhea and was well tolerated, with adverse events similar to that of placebo in the study. In addition, rifamycin SV MMX demonstrated broad activity, and of interest was the possible activity against invasive pathogens," said Herbert L. DuPont, M.D., principal investigator and lead author of the poster. Dr. DuPont is Director of the Center for Infectious Diseases and Professor of Infectious Diseases at the University of Texas -- Houston School of Public Health, Chief of Internal Medicine at St. Luke's Hospital and Vice Chairman, Department of Medicine and Clinical Professor at the Baylor College of Medicine.
The co has previously announced that the Phase III study met the primary endpoint of reducing the time to last unformed stool (TLUS) in the intent-to-treat (ITT) population.
